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Abstract
Burn patients suffer from immunological dysfunction for which there are currently no suc-
cessful interventions. Similar to previous observations, we find that burn shock patients
(15% Total Burn Surface Area (TBSA) injury) have elevated levels of the innate immune
cytokines Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1)/CC-motif
Chemokine Ligand 2(CCL2) early after hospital admission (0–48 Hours Post-hospital
Admission (HPA). Functional immune assays with patient Peripheral Blood Mononuclear
Cells (PBMCs) revealed that burn shock patients (15% TBSA) produced elevated levels of
MCP-1/CCL2 after innate immune stimulation ex vivo relative to mild burn patients. Interest-
ingly, treatment of patient PBMCs with the Nuclear Factor-Erythroid-2-Related Factor 2
(NRF2) agonist, CDDO-Me(bardoxolone methyl), reduced MCP-1 production but not IL-6 or
Interleukin-10 (IL-10) secretion. In enriched monocytes from healthy donors, CDDO-Me
(bardoxolone methyl) also reduced LPS-induced MCP1/CCL2 production but did not alter
IL-6 or IL-10 secretion. Similar immunomodulatory effects were observed with Compound 7,
which activates the NRF2 pathway through a different and non-covalent Mechanism Of
Action (MOA). Hence, our findings with CDDO-Me(bardoxolone methyl) and Compound 7
are likely to reflect a generalizable aspect of NRF2 activation. These observed effects were
not specific to LPS-induced immune responses, as NRF2 activation also reduced MCP-
1/CCL2 production after stimulation with IL-6. Pharmacological NRF2 activation reduced
Mcp-1/Ccl2 transcript accumulation without inhibiting either Il-6 or Il-10 transcript levels.
Hence, we describe a novel aspect of NRF2 activation that may contribute to the beneficial
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effects of NRF2 agonists during disease. Our work also demonstrates that the NRF2 path-
way is retained and can be modulated to regulate important immunomodulatory functions in
burn patient immune cells.
Introduction
Thermal injuries cause approximately 300,000 human deaths per year worldwide and are
among the most expensive traumatic injuries due to long-term hospitalization and wound
treatment [1, 2]. Two major aspects of burn injury are stress-associated pathophysiological
changes and mis-regulated inflammatory responses. Elevated systemic levels of pro- and anti-
inflammatory mediators correlate with mortality in burn patients [2], suggesting a general
immunological dysfunction. Specific examples include the pro-inflammatory cytokines IL-6
and MCP-1 which associate with worse clinical outcomes [3] Conversely, the anti-inflamma-
tory cytokine, IL-10, has been linked with susceptibility to respiratory infections and sepsis-
associated mortality [4, 5] Hence, there is a medical need for new therapeutics that modulate
host responses following burn injury [6].
In the context of disease, an important regulator of host defense against stress and inflam-
mation is Nuclear Factor-Erythroid-2-Related Factor (NRF2). NRF2 is a transcription factor
that regulates over 250 genes [7]. During periods of stress, negative regulation of NRF2 by
KEAP1(Kelch-like ECH-Associated Protein 1) is relieved, allowing NRF2 to accumulate in the
cytoplasm and subsequently translocate to the nucleus and initiate a defense transcriptional
program [7]. NRF2 then binds regulatory sequences known as Anti-oxidant Response Ele-
ments (AREs) or Electrophile Response Elements (EpREs) in the promoters of genes encoding
anti-oxidant, cytoprotective, and phase 2 de-toxifying molecules [7]. Studies with Nrf2-/- mice
have shown that the loss of Nrf2 alters inflammatory cytokine production such as Tumor
Necrosis Factor-Alpha (TNF-α) and Interleukin 1-beta (IL-1β) in murine fibroblasts and mac-
rophages, respectively [8, 9]. These in vitro findings correlate with changes in inflammatory
mediator production in vivo during models of sepsis, peritonitis, and burn injury [8–10].
Additionally, Nrf2-/- deficient peritoneal macrophages produce elevated amounts of Monocyte
Chemoattractant Protein-1 (MCP-1) [11].
MCP-1 was the first discovered chemokine and functions by recruiting monocytes and
T cells to sites of inflammation [12]. The main receptor target for MCP-1 is C-C chemokine
Receptor-2 (CCR2), which is primarily expressed on immune cells [12]. Studies have shown
that monocytes/macrophages are the principle cellular sources of MCP-1 [13]. In mice, sys-
temic MCP-1 levels are increased after thermal injury and are associated with the induction of
type II T cells [14]. Clinical studies have demonstrated that elevated systemic levels of MCP-1
correlate with mortality in burn patients [3]. Hence, MCP-1 is a myeloid-associated factor that
is linked to worse clinical outcomes after thermal injury.
An agonist of the NRF2 pathway is Bardoxolone methyl (CDDO-Me) [15]. CDDO-Me(bar-
doxolone methyl) is a synthetic triterpenoid derived from the natural product oleanic acid
[16]. This small molecule functions through binding specific cysteine residues on KEAP1 and
drives NRF2 protein accumulation and translocation to the nucleus [17]. CDDO-Me(bardoxo-
lone methyl) has been shown to effectively reduce clinical outcomes in murine models of
ischemic and drug-induced kidney injury [18]. Additionally, CDDO-Me(bardoxolone methyl)
is currently in clinical trials for numerous indications including Pulmonary Arterial Hyperten-
sion (PAH) and Chronic Kidney Disease (CKD) but has been demonstrated to hit more
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molecular targets than NRF2 [19, 20]. A recently described small molecule activator of the
NRF2 pathway is Compound 7 which triggers the NRF2 pathway through blocking the inter-
face between KEAP1 and NRF2, in a non-covalent and selective fashion [21]. Hence, both
CDDO-Me(bardoxolone methyl) and Compound 7 activate the NRF2 pathway through differ-
ent biochemical mechanisms [21].
In this study, we demonstrate that patients with moderate/severe(15% TBSA) or pulmo-
nary dysfunction(<357 SpO2/FiO2 ratio) have elevated levels of IL-6 and MCP-1 early(0–48
hours) after hospital admission. LPS-stimulated Peripheral Blood Mononuclear Cells
(PBMCs) from moderate/severe burn patients(15% TBSA) produced elevated amounts of
MCP-1 ex vivo indicating an altered innate immune profile. Treatment of patient PBMCs with
CDDO-Me(bardoxolone methyl) effectively reduced MCP-1 production and induced the
NRF2-target gene NQO1. Using enriched monocyte populations from healthy donors, we find
similar immunomodulatory effects occur with multiple small molecule activators of the NRF2
pathway. NRF2 activation also reduced MCP-1 production in response to the host factor IL-6.
Collectively, we demonstrate a connection between selectively activating the NRF2 pathway




Patients were admitted to the North Carolina Jaycee Burn Center from November 2015 to
October 2016. Following a written informed consent approved by the Institutional Review
Board of the University of North Carolina at Chapel Hill School of Medicine, an initial blood
sample was obtained within the first 48 hours after admission. Additional blood samples were
obtained at 72–144 hours post-hospital admittance. Samples were only collected as ordered for
clinical care. Clinical data including Total Burn Surface Area, age, gender, burn classification
by degree, length of stay, infectious complications, organ function, and mechanical ventilation
were documented throughout the duration of stay in the burn unit. HAI was defined as a posi-
tive bacterial culture from either the bloodstream or respiratory tract. SpO2 / FiO2 ratios were
calculated at 0–24 HPA. For monocytes experiments, source leukocytes from healthy donors
were ordered from Gulf Coast Regional Blood Center. The human biological samples were
sourced ethically and their research use was in accord with the terms of the informed consents.
Patient blood processing
16 cc of blood was collected from burn patients or ~50 cc of blood was collected from healthy
donors (Gulf Coast Regional Blood Center). Blood was overlaid onto Histopaque 1077 (Sigma,
#10771) and centrifuged at 450 x g for 35 minutes. PBMCs were harvested from the interface
and washed 2X with Hank’s Balanced Salt Solution (HBSS) (Sigma, 55021). Cells were then
subjected to Ammonium Chloride Potassium (ACK) (ThermoFisher, A1049201) lysis, filtered
through a 70μM cell strainer (Fisher, 352350), and washed 2X with HBSS (Sigma, 55021). Cells
were counted with a disposable hemocytometer (In-CYTO, C-Chip, DHC-N01).
Cell culture
5 x 105 PBMCs were plated in 200 μL of RPMI 1640 (ThermoFisher, 1875093) with 2%
Human Serum (Sigma, H3667), Beta-mercaptoethanol(Gibco, 21985–027), Sodium Pyruvate
(Gibco, 11360), Non-essential Amino Acids (Gibco, 11140–076) and antibiotics (Gibco,
152140–002) in 96-well plates (Fisher, 351177). Monocyte purification was performed with
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CD14 microbeads(Miltenyi, 130-050-201) according to the manufacturer’s directions. Purified
monocytes were re-suspended in RPMI media(See above) and plated the same as PBMCs.
PBMCs and monocytes were treated with CDDO-Me(bardoxolone methyl)(Sigma-Aldrich,
SMB00376), Vehicle (0.00005% DMSO), Compound 7 [21], or Vehicle (0.001% DMSO) for 1
hour before stimulation with 5 ng/mL of Lipopolysaccheride (LPS) (Sigma-Aldrich, L2630) or
IL-6 (50 ng/mL, Peprotech, 200–06). At indicated times post-stimulation, plates were centri-
fuged at 500 x g for 5 minutes and supernatants were collected. Cell pellets were subjected to
protein or RNA analysis (See below).
Immunoblot analysis
Protein lysates were generated using RIPA buffer (Sigma, R0278) with 1% SDS, 5mM DTT,
Protease Inhibitor (Sigma, p8340), and Phosphatase inhibitors (Sigma-Aldrich, 490684500).
Lysates were resolved on Novex 4–12% gels (Invitrogen, EC6038) and wet-transfer blotting
was performed onto PVDF filter paper (Biorad, 162–01777). Membranes were blocked with
5% milk in a 1X TBST buffer (Thermofisher, 28360) for 1 hour at room temperature. Blots
were washed 3X with 1X TBST and subjected to over-night incubation at 4’C with anti-NQO1
(Abcam, ab34173) or anti-GAPDH-HRP(Cell Signaling, 3683) antibodies. Membranes were
then washed 3X with 1X TBST and incubated for 1 hour at room temperature with an Perioxi-
dase-conjugate AffiniPure Anti-Rabbit IgG antibody (Jackson ImmunoResearch, 111-035-
144). Blots were washed 3X with 1X TBST and developed with Super Signal West Femto
(Thermo Scientific, #34095). Chemiluminescence was measured with a Biorad Chemi-dock
system. ImageJ software was used to quantify the intensity of the NQO1 bands relative to the
intensity of the loading control (GAPDH). For each lane, a ratio of NQO1/GAPDH was gener-
ated and relative values were determined based on setting the NQO1/GAPDH ratio for the
unstimulated, vehicle control-treated cells to 1.
RNA analysis
RNA was isolated using RNeasy Mini Kit(Qiagen, 74106) and cDNA was synthesized using
SuperScript VILO Master Mix Kit(ThermoFisher, 11755050). Real time PCR was performed
for Mcp-1 (ThermoFisher, Hs00234140_m1), Il-6 (ThermoFisher, Hs00174131_m1), Il-10
(ThermoFisher, Hs00961622_m1), Nqo-1 (Thermofisher, Hs01045993_g1), Hmox-1 (Thermo-
fisher, Hs00111025_m1), and Gapdh (Thermofisher, Hs02758991_g1) using TaqMan Gene
Expression Master Mix (Thermofisher, 4369016). Relative target transcript expression to
Gapdh was determined with the 2-ΔΔCT method.
Flow cytometry
~2 x 106 PBMCs or enriched monocytes(CD14+) were washed 2X in FACS buffer(1% PBS
with 2% Fetal Bovine Serum (FBS)) before 1 hour incubation on ice with Human TruStain
FcX (Biolegend, 422302) according to the manufacturer’s directions. Cells were pelleted and
washed 3X with FACS buffer and stained with CD11b-FITC(ebioscience, 11-0118-42) and
HLA-DR-APC(Biolegend, 307610), according the manufacture’s protocol. Stained cells were
acquired using a LSRII Fortessa flow cytometer and analyzed with FlowJo software.
ELISA
Plasma and cellular supernatants were measured using ELISA kits for MCP-1 (BD Biosciences,
555179), IL-6 (BD Biosciences, 555220), TNFα (BD Bioscience, 555212), IL-8 (BD Biosciences,
555244), MCP-2 (CCL8) (Biolegend, 442204), and IL-10 (BD Biosciences, 555157). 1-Step
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Slow TMB ELISA substrate (Thermo Scientific, 34024) and Stop Solution (Invitrogen, 5504)
were used for colorimetric detection.
Statistics
Analysis of Variation (ANOVA), T-tests, Chi Square (with Fisher’s Exact Test) analysis and
interpolation of cytokine values were performed with GraphPad Prism 6 Software.
Results
There were a total of 50 patients admitted that met criteria to be included in our analysis. Clin-
ical characteristics of the burn patient cohort are shown (Table 1). The patient cohort was sub-
divided into mild burn injury (<15% Total Body Surface Area (TBSA) and moderate/severe
burn injury (15% TBSA) groups (Table 1). There were not significant differences between
the groups regarding age, gender, burn type, in-hospital mortality, or the occurrence of inhala-
tion injury (Table 1). Compared to the mild burn injury group, the moderate/severe burn
patient group were supported with Mechanical Ventilation (MV), susceptible to Healthcare-
Associated Infections (HAIs), and had longer Length Of Stays (LOS) (Table 1, P< .01).
Patient blood was subjected to density gradient-based separation allowing for the isolation
of plasma and PBMCs fractions. Systemic inflammatory mediators were evaluated by Enzyme
Linked Immunosorbant Assay (ELISA) analysis in plasma fractions for IL-6 and MCP-1.
Within the first 48 Hours Post-hospital Admittance (HPA), the moderate/severe burn injury
group (15% TBSA) had significantly elevated levels of IL-6 and MCP-1 (Fig 1A and 1B, P<
.0001 and P< .001, respectively). An important resource that is used to quantified the level of
a critical ill patients’ severity of illness is the Sequential Organ Failure Assessment (SOFA)
score [22]. Within the SOFA scoring system, a SpO2/FiO2 ratio of<357 represents dysfunction
of the pulmonary compartment [23]. Independently of burn size, patients that suffered early
pulmonary dysfunction (<357 SpO2/FiO2 ratio) at 0–24 HPA also had significantly heightened
levels of IL-6 and MCP-1 (Fig 1C and 1D, P< .05). Longitudinal analysis of systemic IL-6 and
MCP-1 levels revealed that differences between the mild (<15% TBSA) and moderate/large
(15% TBSA) burn injury groups were most consistent early post-hospital admission (Fig 1E
and 1F and S1 Fig).
Table 1. Burn patient cohort characteristics.
Characteristic All Patients(n = 50) <15% TBSA(n = 28) 15% TBSA(n = 22) P
Age, yrs 43 ± 2 40 ± 3 47 ± 3 0.11
Female 13 (26%) 8 (29%) 5 (23%) 0.75
Flame Burn 33 (66%) 16 (57%) 17 (77%) 0.23
Scald Burn 17 (34%) 12 (43%) 5 (23%) 0.23
% TBSA 15 ± 2 4 ± 1 28 ± 2 <.001
Inhalational Injury 6 (12%) 1 (4%) 5 (23%) 0.07
In-Hospital Mortality 3 (6%) 0 (0%) 3 (14%) 0.08
Mechanical Ventilation 13 (26%) 1 (4%) 12 (55%) <.001
HAI 10 (20%) 0 (0%) 10 (45%) <.001
Length of Hospital Stay 18 ± 4 7 ± 1 36 ± 8 <.001
TBSA, total body surface area; HPA, hours post-hospital admittance; HAI, healthcare associated infection; ±, standard error measurement. T tests were
performed for Age, TBSA, and Length of Hospital Stay. Chi Square(with Fisher’s Exact test) analysis was performed for Female, Flame Burn, Scald Burn,
Inhalational Injury, Hospital Mortality, Mechanical Ventilation, and HAI.
https://doi.org/10.1371/journal.pone.0184164.t001
NRF2 activation attenuates MCP-1 production during innate immune responses
PLOS ONE | https://doi.org/10.1371/journal.pone.0184164 September 8, 2017 5 / 16
Since in many cases the cellular sources of IL-6 and MCP-1 are innate immune cells, we
next evaluated how burn injury influenced the production of these cytokines after innate
immune stimulation. Patient PBMCs were stimulated with LPS and supernatants were assayed
for the production of IL-6 and MCP-1. Interestingly, the moderate/severe burn injury patient
group had no difference in LPS-induced IL-6 secretion but produced more MCP-1 after innate
immune stimulation (Fig 2A and 2B). We next evaluated if treatment of patient PBMCs with
the NRF2 agonist, CDDO-Me(bardoxolone methyl), could lead to functional immune
changes. Treatment with CDDO-Me(bardoxolone methyl) effectively reduced MCP-1 produc-
tion in a concentration-dependent manner (Fig 2C). To assess if CDDO-Me(bardoxolone
methyl)-mediated reduction of MCP-1 production correlated with induction of the NRF2
pathway, immunoblot analysis for NQO1 was performed. Previous studies have shown that
CDDO-Me(bardoxolone methyl)-mediated induction of NQO1 is dependent on NRF2 in
both murine and human cells [21]. Additionally, CDDO-Me(bardoxolone methyl)-mediated
induction of NQO1 protein expression is Nrf2-dependent in vivo [15] and has been used as a
pharmacodynamic marker in patient PBMCs during a phase I clinical trial [24]. Our results
Fig 1. Systemic IL-6 and MCP-1 are elevated in patients with large burn injuries and organ
dysfunction. (A) Scatter plot analysis of systemic IL-6 levels between mild (<15% TBSA, Black circles) and
moderate/severe (15% TBSA, Red squares) patients at 0–48 HPA. (B) Scatter plot analysis of systemic
MCP-1 levels between mild (<15% TBSA, Black circles) and moderate/severe (15% TBSA, Red squares)
patients at 0–48 HPA. (C) Scatter plot analysis of systemic IL-6 levels between burn patients that suffer
pulmonary distress(0–24 HPA, <357 SpO2/FiO2 ratio) and patients that did not (>357 SpO2/FiO2 ratio). (D)
Scatter plot analysis of systemic MCP-1 levels between burn patients that suffer pulmonary distress(0–24
HPA, <357 SpO2/FiO2 ratio) and patients that did not (>357 SpO2/FiO2 ratio). (E) Line plot representing
longitudinal analysis of systemic IL-6 accumulation from 0–48 HPA and 72–144 HPA timepoints. (F) Line plot
representing longitudinal analysis of systemic MCP-1 accumulation from 0–48 HPA and 72–144 HPA
timepoints. Error bars represent ± SEM. T-tests were performed to determine statistical significance for (A-D).
**** represents P < .0001, *** represent P < .001, * represent P < .05.
https://doi.org/10.1371/journal.pone.0184164.g001
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demonstrate that CDDO-Me-(bardoxolone methyl) induced NQO1 accumulation in patient
PBMCs in a concentration-dependent manner (Fig 2D). The intensity of NQO1 expression
depicted in Fig 2D was quantified (S2 Fig).
The analysis was expanded across the burn patient cohort and we found that treatment of
PBMCs with CDDO-Me(bardoxolone methyl) significantly reduced LPS-induced MCP-1 pro-
duction but had no distinct effects on either IL-6 or IL-10 secretion (Fig 3A and 3C). Measure-
ment of the percent reduction of cytokine secretion across the patient cohort revealed that
CDDO-Me(bardoxolone methyl) reduced MCP-1 production to ~20% while having limited
effects on LPS-induced IL-6 and IL-10 secretion(~107% and ~110%, respectively (Fig 3D).
Since PBMCs are a heterogenous population of mononuclear immune cells (Monocytes, T
cells, B cell, NK cells, etc.), we assessed if activating the NRF2 pathway could effectively modu-
late MCP1 production within a homogenous monocyte population. Monocytes were enriched
from healthy donor PBMC populations (S3 Fig) and stimulated as was performed with patient
PBMCs. ELISA analysis revealed that CDDO-Me(bardoxolone methyl) inhibited LPS-induced
MCP-1 production but did not reduce IL-6 or IL-10 secretion at any of the time points mea-
sured (Fig 4A). Measurement of the percentage reduction in cytokine secretion across a set of
5 independent donors revealed that CDDO-Me(bardoxolone methyl) reduced MCP-1 produc-
tion to ~15% at 16 hours post-LPS stimulation and ~30% at 24 hours post-LPS stimulation
Fig 2. Pharmacological NRF2 activation reduced MCP-1 production in patient PBMCs after innate
immune stimulation. (A) ELISA analysis in mild (<15% TBSA, Black circles) and moderate/severe (15%
TBSA, Red squares) patient PBMCs (0–72 HPA) for IL-6 and MCP-1 in the absence (-) and presence (+) of
LPS (5 ng/mL). (B) ELISA analysis in mild (<15% TBSA, Black circles) and moderate/severe (15% TBSA,
Red squares) patient PBMCs (0–72 HPA) for IL-6 and MCP-1 in the absence (-) and presence (+) of LPS
(5 ng/mL). (C) ELISA Analysis of 4 representative patients(#1–4) 24 hours post-LPS stimulation. CDDO-Me
(bardoxolone methyl) concentrations are in 50 and 5 nM, respectively. (D) Immunoblot analysis of 4
representative patients (#1–4) at 24 hours post-LPS stimulation. CDDO-Me(bardoxolone methyl)
concentrations are in 50 and 5 nM, respectively. Error bars represent ± SEM. ANOVA analysis with Tukey
post-hoc analysis was performed to determine statistical significance in A. **** = p < .0001. *** = p < .001.
* = p < .05.
https://doi.org/10.1371/journal.pone.0184164.g002
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(Fig 4B). Additionally, CDDO-Me(bardoxolone methyl) did not reduce IL-6 or IL-10 produc-
tion (Fig 4B). For both NRF2 agonists, we did observe a trend towards elevated IL-10 produc-
tion at 16 hours post-LPS stimulation (Fig 4B and 4E). CDDO-Me(bardoxolone methyl) also
did not reduce LPS-triggered TNFα production at 4, 8, and 16 hours post-stimulation (S4 Fig).
Additionally, CDDO-Me(bardoxolone methyl) did not attenuate LPS-triggered IL-8 produc-
tion but did reduce production of MCP-2 (S5 Fig). The reduction of MCP-1 correlates with
induction of NQO1 expression (Fig 4C), indicating activation of the NRF2 pathway.
We next evaluated a second, independently synthesized, NRF2 agonist to determine if
MCP-1 reduction was a general aspect of pharmacological NRF2 activation. Compound 7 is a
new and selective small molecule activator of the NRF2 pathway that functions through block-
ing the KEAP1-NRF2 interface [21]. Hence, Compound 7 activates the NRF2 pathway through
a different molecular Mechanism Of Action (MOA) than CDDO-Me(bardoxolone methyl).
We found that Compound 7 also reduced MCP-1 production without affecting LPS-induced
IL-6 or IL-10 production (Fig 4D). Measurement of the percentage reduction in cytokine
secretion across 4 independent donors revealed that Compound 7 reduced MCP-1 production
Fig 3. Pharmacological NRF2 activation reduced MCP-1 production in burn patients immune cells. (A) Line plot
representing the CDDO-Me(bardoxolone methyl)(50 nM)-mediated changes in MCP-1 production across 30 patients (0–72
HPA). Red squares and lines indicate moderate/severe burn group (15% TBSA) while black circles and lines represent mild
burn group (<15% TBSA). (B) Line plot representing the CDDO-Me(bardoxolone methyl)(50 nM)-mediated changes in IL-6
production across 29 patients (0–72 HPA). Red squares and lines indicate moderate/severe burn group (15% TBSA) while
black circles and lines represent mild burn group (<15% TBSA). (C) Line plot representing the CDDO-Me(bardoxolone methyl)
(50 nM)-mediated changes in IL-10 production across 23 patients (0–72 HPA). Red squares and lines indicate moderate/severe
burn group (15% TBSA) while black circles and lines represent mild burn group (<15% TBSA). (D) Bar graph depicting the
percentage of CDDO-Me(bardoxolone methyl)-altered cytokine production for MCP-1, IL-6, and IL-10. Relative values were
combined across the patient cohort (N = 30 for MCP-1, N = 29 for IL-6, N = 23 for IL-10). Error bars represent ± SEM.
https://doi.org/10.1371/journal.pone.0184164.g003
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to ~40% at 16 hours post-LPS stimulation (Fig 4E). Additionally, inhibition of MCP-1 produc-
tion by Compound 7 correlated with target engagement as measured by elevated NQO1
expression (Fig 4F).
Systemic IL-6 is elevated in burn shock patients and correlates with an increased risk of
mortality [3]. In vitro studies have demonstrated that IL-6 can induce MCP-1 production in
Fig 4. Multiple NRF2 agonists reduce MCP-1 production in enriched monocyte populations. (A) ELISA analysis for MCP-1, IL-6, and
IL-10 in healthy donor monocytes after treatment with CDDO-Me(bardoxolone methyl) (50nM) at indicated Hours Post-LPS Stimulation
(HPS). Results are representative of 5 independent donors. (B) Bar graph depicting the percentage of CDDO-Me(bardoxolone methyl)-
altered cytokine production for MCP-1, IL-6, and IL-10 at 16 and 24 HPS. Relative values represent the combination of 5 independent sets of
healthy donor monocytes. (C) Immunoblot analysis demonstrating the kinetics of NQO1 expression after treatment with CDDO-Me
(bardoxolone methyl) (50nM). Results are representative of 5 independent donors. (D) ELISA analysis for MCP-1, IL-6, and IL-10 in healthy
donor monocytes after treatment with Compound 7 (1 μM) at 16 HPS. Results are representative of 4 independent donors. (E) Bar graph
depicting the percentage of Compound 7-altered cytokine production for MCP-1, IL-6, and IL-10 at 16 HPS. Relative values represent the
combination of 4 independent sets of healthy donor monocytes. (F) Immunoblot analysis demonstrating NQO1 expression after treatment
with Compound 7 (1 μM) at 16 HPS. Results are representative of 4 independent donors. Error bars represent SEM. ** = p < .01.
*** = p < .001. **** = p < .0001.
https://doi.org/10.1371/journal.pone.0184164.g004
Fig 5. NRF2 activation attenuated IL-6-induced MCP-1 production. (A) ELISA analysis for MCP-1 in
healthy donor monocytes after treatment with CDDO-Me(bardoxolone methyl) (50nM) at indicated Hours
Post-IL-6 Stimulation (HPS). Results are representative of 4 independent donors. (B) Bar graph depicting the
percentage of CDDO-Me(bardoxolone methyl)-altered MCP-1 production at 16 HPS. Relative values
represent the combination of 4 independent sets of healthy donor monocytes. (C) Immunoblot analysis
demonstrating NQO1 expression after treatment with CDDO-Me(bardoxolone methyl) (50nM) at 16 HPA.
Results are representative of 2 independent donors. (D) ELISA analysis for MCP-1 in healthy donor
monocytes after treatment with Compound 7 (1 μM) at 16 HPS. Results are representative of 2 independent
donors. Error bars represent SEM. * = p < .05. ** = p < .01. *** = p < .001. **** = p < .0001.
https://doi.org/10.1371/journal.pone.0184164.g005
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human PBMCs and monocytic cell lines [25, 26]. We therefore evaluated if pharmacological
NRF2 activation could attenuate IL-6-induced MCP-1 secretion in enriched monocyte popula-
tions. We found that both CDDO-Me(bardoxolone methyl) and Compound 7 reduced MCP-
1 production in response to IL-6 (Fig 5A and 5B). These findings correlated with target
engagement as measured by elevated NQO1 expression (Fig 5C and 5D). Unlike LPS treat-
ment, IL-6 stimulation alone did not result in elevated NQO1 expression (Figs 4 and 5). Col-
lectively, these results demonstrate that pharmacological NRF2 activation reduced MCP-1
production in response to both bacterial components (LPS) and host factors (IL-6) which are
elevated in burn shock patients.
We next evaluated if the suppression of MCP-1 production by pharmacological NRF2 acti-
vation was due to reduced accumulation of Mcp-1 transcript. Real time PCR analysis revealed
that NRF2 activation with CDDO-Me(bardoxolone methyl) reduced Mcp-1 transcript levels
but did not inhibit LPS-induced transcript accumulation of either Il-6 or Il-10 (Fig 6). Addi-
tionally, the percentage reduction of LPS-induced transcript accumulation across >5 indepen-
dent donors revealed that CDDO-Me(bardoxolone methyl) reduced Mcp-1 transcript levels to
~30%, ~10%, and ~40% at 4, 8, and 16 hours post-LPS stimulation while having limited effects
on Il-6 and Il-10 transcript accumulation, although there was trend toward higher il-10 tran-
cript levels at 16 hours post-LPS stimulation (Fig 6E and 6G). NRF2 activation with
CDDO-Me(bardoxolone methyl) also induced Nqo-1 expression (Fig 6D and 6H). In agree-
ment with previously published findings [9], we found that LPS stimulation alone induced
both Nqo-1 transcript and NQO1 protein expression (Figs 4 and 6). Additionally, NRF2 activa-
tion with CDDO-Me(bardoxolone methyl) also induced Ho-1 expression (S6 Fig).
Fig 6. Pharmacological NRF2 activation inhibits Mcp-1 transcript accumulation. (A) Real time PCR
analysis for Mcp-1 in healthy donor monocytes treated with CDDO-Me(bardoxolone methyl) (50nM). Values
are relative to unstimulated, vehicle treated cells at indicated Hours Post-LPS Stimulation (HPS). Results are
representative of 8 independent donors. (B) Real time PCR analysis for Il-6 in healthy donor monocytes
treated with CDDO-Me(bardoxolone methyl) (50nM). Values are relative to unstimulated, vehicle treated cells
at indicated HPS. Results are representative of 6 independent donors. (C) Real time PCR analysis for Il-10 in
healthy donor monocytes treated with CDDO-Me(bardoxolone methyl) (50nM). Values are relative to
unstimulated, vehicle treated cells at indicated Hours Post-LPS Stimulation (HPS). Results are representative
of 6 independent donors. (D) Real time PCR analysis for Nqo-1 in healthy donor monocytes treated with
CDDO-Me(bardoxolone methyl) (50nM). Values are relative to unstimulated, vehicle treated cells at indicated
HPS. Results are representative of 4 independent donors. (E) Bar graph representing the combination of
CDDO-Me(bardoxolone methyl)-altered Mcp-1 transcript accumulation in 8 donors. (F) Bar graph
representing the combination of CDDO-Me(bardoxolone methyl)-altered Il-6 transcript accumulation in 6
donors. (G) Bar graph representing the combination of CDDO-Me(bardoxolone methyl)-altered Il-10 transcript
accumulation in 6 donors. (H) Bar graph representing the combination of CDDO-Me(bardoxolone methyl)-
altered Nqo-1 transcript accumulation in 4 donors. Error bars represent SEM. * = p < .05. ** = p < .01.
*** = p < .001. **** = p < .0001.
https://doi.org/10.1371/journal.pone.0184164.g006
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Discussion
Patients with severe thermal injury have dysregulated immune responses which are associated
with worse clinical outcomes. Burn size as represented by TBSA, is a major factor that corre-
lates with hyper-activity of the innate immune system [27]. Additionally, burn patients with
higher TBSA values are most likely to suffer from HAIs, organ failure, and mortality. Unfortu-
nately, many therapeutic strategies targeting immune responses such as inhibitors of prosta-
glandin synthesis or glucocorticoids impair wound healing [28]. Hence, there is medical need
for novel treatment options that target the host immune response to thermal injury.
MCP-1 is a multifaceted component of the immune system that has numerous genetic and
therapeutic connections to human disease. Genetic polymorphisms in Mcp-1 are associated
with carotid intima-media thickness(atherosclerosis) in stroke patients [29]. Elevated systemic
MCP-1 levels are associated with worse outcomes in patients with cardiovascular disease and
thermal injury [3, 30]. Additionally, Acute Respiratory Distress Syndrome (ARDS) patients
have heightened pulmonary accumulation of MCP-1 [31]. From a mechanistic standpoint,
MCP-1 play a pathogenic role through recruitment of Metastasis-Associated Macrophages
(MAMs) to the tumor microenvironment in breast cancer animal models [32]. In human
PBMCs, MCP-1 is sufficient to promote an alternative activation (M2) profile. [26]. Therapeu-
tically inhibiting MCP-1 synthesis leads to better clinical outcomes in animal models of sepsis
and endotoxemia [33]. Importantly, biologic-based depletion strategies have shown limited
efficacy in sustaining reduction of systemic MCP-1 levels in patients [34]. Hence, targeting
transcriptional accumulation of Mcp-1 through pharmacological NRF2 activation may provide
unique benefit.
Both genetic and therapeutic studies have demonstrated a protective role for the NRF2
pathway during disease. Characterization of Nrf2-/- mice have shown that the NRF2 pathway
has a beneficial function in models of Acute Kidney Injury (AKI), Atherosclerosis, and Sepsis
[8, 35, 36]. In response to severe burn injury, Nrf2-/- mice suffered higher levels of mortality
[10]. The elevated mortality in Nrf2-/- mice correlated with 1) pulmonary immune cell infiltra-
tion, 2) elevated systemic levels of pro-inflammatory cytokines, and 3) intestinal permeability
[10]. Additionally, in vivo activation of the NRF2 pathway led to improved physiological out-
comes in an animal model of pulmonary hypertension [36]. In humans, genetic polymor-
phisms and expression of Keap1 and Nrf2 are associated with tumorigenesis and clinical
outcomes in cancer patients [37]. Genetic polymorphisms in Nrf2 are also associated with
blood pressure and cardiovascular mortality in hemodialysis patients [38]. In the context of
critical care, functional polymorphisms in Nrf2 are associated with an increased risk for the
development of Acute Lung Injury (ALI) [39]. Additionally, whole blood expression analysis
from septic shock patients revealed the upregulation of 123 NRF2-modulated genes [40].
The role of the NRF2 pathway during innate immune signaling is complex due to variable
host genetic systems (Nrf2-/-, Keap1-/-), and the usage of different small molecule activators of
the NRF2 pathway (Dimethyl Fumarate, Sulforaphane, CDDO-Me(bardoxolone methyl),
Compound 7, Diethylmaleate (DEM), etc.). It is imprudent to assume that pharmacological
activation of the NRF2 pathway will have the opposite biological effect than Nrf2 genetic defi-
ciency. Using Nrf2-/- mice, studies have shown that peritoneal macrophages and Mouse
Embryonic Fibroblasts (MEFs) have enhanced NF-κB signaling which coincided with height-
ened TNFα production [8, 10]. Keap1-/- deficient mice, which have elevated NRF2 activation,
have reduced transcript accumulation of Il-6 and Il-1β but not Tnfα in murine Bone Marrow-
derived Macrophages (BMMs) [41]. Additionally, NRF2 activation with DEM(100 μM)
reduced Il-6 and Il-1β transcript accumulation in both murine BMMs and immortalized
human monocyte cells (THP-1) [41]. This work also demonstrated that NRF2 activation with
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DEM(100 μM) did not alter NF-κB p65 recruitment to the Il-6 and Il-1β promoters [41]. Alter-
natively, BMM from Nrf2-/- mice produce reduced amounts of IL-1β [9], indicating a positive
role of NRF2 in promoting immune responses. TLR-induced NF-κB signaling is required for
Nlrp3 expression and therefore subsequent NLRP3 inflammasome function [42]. Hence, fur-
ther mechanistic studies are required to evaluate the relationship between NRF2 activation,
innate immune cytokine production, and crosstalk with the NF-κB pathway. It is possible that
different levels of NRF2 activation may induce unique immunomodulatory effects regarding
innate immune cytokine production and the NF-κB pathway. This possibility is consistent
with the findings that pharmacological NRF2 activation can induce either apoptosis or cyto-
protection based on compound dosage.
In PBMCs and monocytes from sepsis patients, CDDO-Me(bardoxolone methyl) treatment
did not reduce LPS-induced Il-6 transcript accumulation although there was target engage-
ment as measured by elevated expression of Nqo-1 [43]. Using patient PBMCs and monocytes,
we found that multiple, independently synthesized, small molecule activators of the NRF2
pathway (CDDO-Me(bardoxolone methyl), Compound 7) reduced MCP-1 production but
did not reduce either IL-6 or IL-10. CDDO-Me(bardoxolone methyl) and Compound 7 target
the KEAP1-NRF2 complex through different biochemical mechanisms [17, 21]. Hence, our
immunological findings represent a potentially generalizable aspect of pharmacological NRF2
activation that occurs with multiple stimuli (LPS, IL-6) and is consistent across >60 individual
human samples. As with many therapeutic interventions, different dosages of NRF2 agonists
may lead to qualitatively different biological and/or immunomodulatory effects [44].
Small molecule agonists of the NRF2 pathway are in various stages of clinical development.
Dimethyl Fumarate(Tecfidera) is an effective treatment for Multiple Sclerosis patients and has
been shown to induce NRF2 activity in patients [45]. Sulforaphane is currently in a small,
phase II clinical trial for the treatment of Chronic Obstructive Pulmonary Disease
(NCT01335971) [46]. Finally, CDDO-Me(bardoxolone methyl) is in phase II/III clinical trials
for Pulmonary Arterial Hypertension (PAH), Chronic Kidney Disease (CKD), and Type II
Diabetes [47]. Hence, there is substantial precedence for targeting the NRF2 pathway during
human disease.
We demonstrate that induction of the NRF2 pathway has immunological properties that
could be beneficial in numerous contexts. It is worth noting that a phase III trial with
CDDO-Me(bardoxolone methyl) for Chronic Kidney Disease (CKD) was terminated due to
adverse cardiovascular events in a patient population with severe kidney disease [47] although
there are currently ongoing phase II trials for CKD, Type II Diabetes, and Pulmonary Arterial
Hypertension (PAH) (NCT02316821, NCT02036970). Therefore, there is a substantial need
for additional chemical entities such as Compound 7 that induce the NRF2 pathway in a selec-
tive fashion. NRF2 agonists are currently in clinical development for chronic pulmonary and
renal indications, we demonstrate that this pathway has immunomodulatory characteristics
that could be beneficial in the context of severe acute illness.
Supporting information
S1 Fig. Measurement of systemic IL-6 and MCP-1 levels in burn patients at 72–144 HPA.
(A) Scatter plot analysis of systemic IL-6 levels between mild (<15% TBSA, Black circles) and
moderate/severe (15% TBSA, Red squares) patients at 72–144 HPA. (B) Scatter plot analysis
of systemic MCP-1 levels between mild (<15% TBSA, Black circles) and moderate/severe
(15% TBSA, Red squares) patients at 72–144 HPA. Error bars represent ± SEM.
(TIF)
NRF2 activation attenuates MCP-1 production during innate immune responses
PLOS ONE | https://doi.org/10.1371/journal.pone.0184164 September 8, 2017 12 / 16
S2 Fig. Quantification of NQO1 expression in burn patient PBMCs. (A) Relative intensity
of NQO1 expression ratio among the indicated treatment groups. Values are relative to unsti-
mulated, vehicle-treated PBMCs for each patient. In the figure legend, values represent nM
concentrations of CDDO-Me(bardoxolone methyl). Results represent the combination of the
4 patient samples shown in Fig 2D. Error bars represent ± SEM.
(TIF)
S3 Fig. Enrichment of monocytes from a PBMC population. (A) Top. Dot plot analysis
depicting Forward and Side Scatter Events (K) after CD14 microbead-mediated enrichment.
Bottom. Dot plot analysis depicted expression of the monocyte markers HLA-DR and CD11b
in cell populations after CD14 microbead-mediated enrichment. Results are representative of
2 independent donors.
(PNG)
S4 Fig. Pharmacological NRF2 activation does not reduce LPS-induced TNFα production.
(A) ELISA analysis for TNFα in healthy donor monocytes after treatment with CDDO-Me
(bardoxolone methyl) (50nM) at indicated Hours Post-LPS Stimulation (HPS). Results are
representative of 5 independent donors. (B) Bar graph depicting the percentage of CDDO-Me
(bardoxolone methyl)-altered TNFα production at 4, 8, 16 HPS. Relative values represent the
combination of 5 independent sets of healthy donor monocytes. Error bars represent SEM.
(TIF)
S5 Fig. Pharmacological NRF2 activation does not alter LPS-induced IL-8 production but
reduces MCP-2 production. (A) ELISA analysis for IL-8 in healthy donor monocytes after
treatment with CDDO-Me(bardoxolone methyl) (50nM) at indicated Hours Post-LPS Stimu-
lation (HPS). Results are representative of 3 independent donors. (B) Bar graph depicting the
percentage of CDDO-Me(bardoxolone methyl)-altered IL-8 production at 4, 8, 16, 24 HPS.
Relative values represent the combination of 3–4 independent sets of healthy donor mono-
cytes. (C) ELISA analysis for MCP-2 in healthy donor monocytes after treatment with
CDDO-Me(bardoxolone methyl) (50nM) at indicated Hours Post-LPS Stimulation (HPS).
Results are representative of 7 independent donors. (D) Bar graph depicting the percentage of
CDDO-Me(bardoxolone methyl)-altered MCP-2 production at 4, 8, 16, 24 HPS. Relative val-
ues represent the combination of 7 independent sets of healthy donor monocytes. ns = not sig-
nificant. Error bars represent SEM.  = p< .05.
(TIF)
S6 Fig. Pharmacological NRF2 activation induces Ho-1 expression. (A) Real time PCR anal-
ysis for Heme Oxygenase-1(Ho-1) in healthy donor monocytes treated with CDDO-Me(bar-
doxolone methyl) (50nM). Values are relative to unstimulated, vehicle treated cells at 16
Hours Post-LPS Stimulation (HPS). Results are representative of 2 independent donors. Error
bars represent SEM.  = p< .05.
(TIF)
S7 Fig. Supporting information. Raw data values for all graphs.
(XLSX)
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